Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Down 5.0% Today

What is Intellia Therapeutics, Inc.?

Intellia Therapeutics Inc. (NASDAQ: NTLA) is a clinical-stage gene editing company specializing in CRISPR-based therapies. The stock showed significant bearish movement recently.

Why is Intellia Therapeutics, Inc. going down?

NTLA stock is down 5.0% on Mar 26, 2025 16:21

• Speculations around the FDA's RMAT designation for Nexiguran Ziclumeran may have initially raised investors' expectations, potentially triggering profit-taking once the news was fully incorporated into the stock value.
• Ongoing shareholder investigations and lawsuits may have fostered uncertainty and negative sentiment towards the company, prompting some investors to liquidate their holdings.
• With the lead plaintiff deadline on the horizon, investors could be apprehensive about potential legal repercussions, likely contributing to the stock's bearish performance.

NTLA Price Chart

NTLA Technical Analysis

NTLA News

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy ( RMAT ) Designation Granted to Nexiguran Ziclumeran ( nex-z ) for the Treatment of Transthyretin ( ATTR ) Amyloidosis with Cardiomyopathy

CAMBRIDGE, Mass., March 26, 2025 ( GLOBE NEWSWIRE ) -- Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) , a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the U.S.

https://www.globenewswire.com/news-release/2025/03/26/3049528/0/en/Intellia-Therapeutics-Announces-FDA-Regenerative-Medicine-Advanced-Therapy-RMAT-Designation-Granted-to-Nexiguran-Ziclumeran-nex-z-for-the-Treatment-of-Transthyretin-ATTR-Amyloidosi.html

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics - Intellia Therapeutics ( NASDAQ:NTLA )

Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Intellia To Contact Him Directly To Discuss Their Options

https://www.benzinga.com/pressreleases/25/03/g44450068/shareholder-action-reminder-faruqi-faruqi-llp-investigates-claims-on-behalf-of-investors-of-intell

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Therapeutics, Inc. Lawsuit - NTLA - Intellia Therapeutics ( NASDAQ:NTLA )

NEW YORK, March 20, 2025 ( GLOBE NEWSWIRE ) -- The Gross Law Firm issues the following notice to shareholders of Intellia Therapeutics, Inc. NTLA. Shareholders who purchased shares of NTLA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff ...

https://www.benzinga.com/pressreleases/25/03/g44421488/the-gross-law-firm-reminds-shareholders-of-a-lead-plaintiff-deadline-of-april-14-2025-in-intellia-

Trending Today

Pepe ($PEPE) Crypto Forecast: Down 5.3% Today

dogwifhat ($WIF) Crypto Forecast: Down 7.2% Today

Sonic (prev. FTM) ($S) Crypto Forecast: Down 10.9% Today

Sui ($SUI) Crypto Forecast: Down 8.7% Today

Toncoin ($TON) Crypto Forecast: Down 6.8% Today

Bonk ($BONK) Crypto Forecast: Down 10.1% Today

Dogecoin ($DOGE) Crypto Forecast: Down 5.9% Today

XRP ($XRP) Crypto Forecast: Down 7.1% Today

Shiba Inu ($SHIB) Crypto Forecast: Down 5.3% Today

Binance Coin ($BNB) Crypto Forecast: Down 5.2% Today

Intellia Therapeutics, Inc. Price History

04.02.2025 - NTLA Stock was down 10.6%

• NTLA's stock experienced a bearish movement possibly due to the looming class action securities lawsuit against the company, creating uncertainty and negative sentiment among investors.
• Despite reporting better-than-expected Q4 results, the narrower loss and increased revenues might not have been enough to offset concerns surrounding the legal issues the company is facing.
• The reminders from law firms about class action lawsuits against NTLA and other companies could have added to the negative pressure on the stock, leading to the bearish movement.
• Investors may be cautious about the potential implications of the legal challenges on NTLA's future performance, contributing to the downward trend in the stock price.

05.02.2025 - NTLA Stock was up 8.5%

• Intellia Therapeutics reported better-than-expected fourth-quarter 2024 results, with a narrower loss than estimates and an increase in revenues year over year. This positive financial performance likely contributed to the bullish movement in the stock.
• The inducement grants awarded to eleven new employees may indicate the company's confidence in its future growth and development, which could have instilled optimism among investors.
• Despite facing a class action lawsuit deadline, the company's ability to surpass revenue estimates and deliver positive surprises in earnings for the quarter ended December 2024 could have boosted investor sentiment and led to the bullish market movement.

18.02.2025 - NTLA Stock was down 5.7%

• The bearish movement in NTLA could be attributed to the pending class action lawsuits and investigations by multiple law firms, leading to uncertainty and potential legal liabilities for the company.
• Investors may be concerned about the impact of these legal proceedings on Intellia's financial stability and future prospects, prompting them to sell off their positions in the stock.
• The selling pressure on NTLA could have been exacerbated by Cathie Wood's Ark Invest offloading its holdings in the company.

20.02.2025 - NTLA Stock was down 5.4%

• NTLA stock witnessed a significant downward trend.
• Notices from law firms and upcoming class action lawsuits against the company might have influenced the negative market sentiment.
• Investors seem worried about potential legal consequences and financial risks linked to ongoing legal inquiries and lawsuits, resulting in a sell-off of NTLA shares.
• The ambiguity concerning legal processes and approaching deadlines could be impacting the stock price, contributing to today's bearish movement.

26.02.2025 - NTLA Stock was down 5.0%

• Speculations around the FDA's RMAT designation for Nexiguran Ziclumeran may have initially raised investors' expectations, potentially triggering profit-taking once the news was fully incorporated into the stock value.
• Ongoing shareholder investigations and lawsuits may have fostered uncertainty and negative sentiment towards the company, prompting some investors to liquidate their holdings.
• With the lead plaintiff deadline on the horizon, investors could be apprehensive about potential legal repercussions, likely contributing to the stock's bearish performance.

28.01.2025 - NTLA Stock was down 9.5%

• Despite reporting a narrower loss than estimates and an increase in revenues, NTLA experienced a bearish movement, indicating that the market may have had higher expectations.
• The reminder of class action lawsuits against Intellia Therapeutics might have created uncertainty among investors, leading to a sell-off of the stock.
• The market could be reacting to the overall sentiment towards gene editing companies, with investors possibly taking a cautious approach towards this sector.
• The strong bearish movement could also be influenced by profit-taking activities from traders who may have been holding the stock for a while, looking to capitalize on the recent positive news.

11.02.2025 - NTLA Stock was down 5.6%

• The bearish movement in NTLA's stock today could be attributed to the multiple class action lawsuits filed against the company by different law firms, which may have raised concerns among investors about potential legal liabilities and financial implications.
• The announcement of inducement grants to new employees might have also contributed to the negative sentiment, as it could signal increased expenses for the company at a time when investors are already cautious.
• The overall legal uncertainty surrounding NTLA, as highlighted by the shareholder reminders and class action suit deadlines, likely weighed on the stock and led to the bearish market movement today.

11.02.2025 - NTLA Stock was down 9.3%

• The bearish movement in Intellia Therapeutics' stock (NTLA) could be attributed to the multiple class action lawsuits being filed against the company.
• The negative investor sentiment following the reports of losses exceeding $50,000 and the reminder for shareholders to discuss their options with legal firms might have further contributed to the downward trend in the stock price.
• The inducement grants awarded to new employees under Nasdaq listing rules may not have been sufficient to offset the concerns raised by the ongoing legal actions, leading to increased selling pressure on the stock.
• Overall, the legal uncertainties surrounding Intellia Therapeutics seem to have overshadowed its innovative CRISPR-based therapies, impacting the market sentiment and driving the bearish movement in the stock.

25.02.2025 - NTLA Stock was down 5.5%

• NTLA stock's decline may be linked to current legal inquiries and lawsuits by shareholder representation, causing doubts and a negative outlook for the company.
• Investors might worry about the financial consequences of these legal battles on Intellia Therapeutics, resulting in stock sell-offs.
• Shareholders facing deadlines to join the lawsuits could heighten stock price pressures, casting uncertainty on the company's near-term prospects.

27.01.2025 - NTLA Stock was up 5.0%

• Q4 earnings and revenue of Intellia Therapeutics exceeded expectations, suggesting a positive financial performance and growth potential.
• The company's positive financial results, along with operational updates, likely contributed to an increase in investor confidence and the upward movement of the stock.
• Despite ongoing class action lawsuits related to securities law violations, investors seem to be emphasizing Intellia's recent achievements and financial stability, driving the bullish trend in NTLA stock.
• Investor optimism regarding Intellia's future in the gene editing sector appears to outweigh concerns about the legal challenges the company is currently confronting.

27.01.2025 - NTLA Stock was up 5.9%

• Despite facing recent lawsuits and legal challenges, NTLA's bullish movement could be attributed to the positive financial results and operational highlights announced for the fourth quarter of 2024.
• The market seems to be reacting favorably to Intellia's progress in revolutionizing medicine with gene editing technologies, overshadowing the legal uncertainties surrounding the company.
• Investors might be optimistic about NTLA's future prospects and the potential of its CRISPR-based therapies, leading to increased buying activity and driving the stock price higher.
• The lawsuits and legal issues, while concerning, do not appear to have significantly dampened investor sentiment towards Intellia Therapeutics, emphasizing the market's confidence in the company's innovative approach to medicine.

17.02.2025 - NTLA Stock was up 6.0%

• Investor confidence in NTLA seemed to drive the bullish movement, despite an ongoing securities class action investigation.
• The approaching deadline for investors to address their losses with legal firms possibly created a sense of urgency, leading to increased trading activity and a positive market response for NTLA.
• Speculations about Cathie Wood's Ark Invest adjusting their holdings and potentially increasing their stake in Intellia Therapeutics may have also contributed to the bullish movement, hinting at long-term growth prospects for the company.
• Despite ongoing investigations and alerts for investors who faced losses, a positive market sentiment persists for NTLA, pushing the stock price upwards.